|Bid||0.00 x 1100|
|Ask||0.00 x 1100|
|Day's Range||6.65 - 6.83|
|52 Week Range||3.97 - 12.50|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.51|
Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules. The company is leveraging its drug delivery technology, DehydraTECH(TM), in the development of hypertension and anti-viral treatments — a big achievement already making an impact in the pharmaceutical industry. “Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far,
New York, New York--(Newsfile Corp. - October 20, 2021) - PCG Digital -- Lexaria Bioscience Corp, developers of the revolutionary DehydraTECH™ drug delivery technology, is in the news again this week. On October 13th, the British Columbia-based pharmaceutical company released study results on THC-A21-1, a THC oral format. The study revealed that Lexaria's DehydraTECH™ THC delivers THC levels to blood-plasma at a rate that is roughly three times faster than standard MCT-based THC. Oral ...
Kelowna, British Columbia – TheNewswire - October 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is ple...